• We are dedicated to supporting the discovery and development of novel diagnostics and therapeutic targets that help to save lives and improve the quality of life of cancer patients. We are dedicated to supporting the discovery and development of novel diagnostics and therapeutic targets that help to save lives and improve the quality of life of cancer patients.
  • We are fuelled by tissue-based Dx test development and validation. We are fuelled by tissue-based Dx test development and validation.
  • We wish to collaborate with partners focused on cancer drug development. Let's start the Rx-Dx process early. We wish to collaborate with partners focused on cancer drug development. Let's start the Rx-Dx process early.
  • Our biomarker DISCOVERY focus is to identify biomarkers and therapeutic targets for cancer. Our biomarker DISCOVERY focus is to identify biomarkers and therapeutic targets for cancer.
  • Our biomarker DETECTION focus uses our IHC-MARK software tool and other off-the-shelf algorithms to make automated quantitation easy. Our biomarker DETECTION focus uses our IHC-MARK software tool and other off-the-shelf algorithms to make automated quantitation easy.
  • AngioTox will predict which patients are prone to cancer drug toxicity side effects AngioTox will predict which patients are prone to cancer drug toxicity side effects
  • FAST-PATH will create faster tools to diagnose Prostate Cancer FAST-PATH will create faster tools to diagnose Prostate Cancer
  • AngioPredict will predict which cancer patients will respond positively to treatment AngioPredict will predict which cancer patients will respond positively to treatment
  • RATHER targets untreatable and aggressive forms of Breast Cancer RATHER targets untreatable and aggressive forms of Breast Cancer
  • Target Melanoma will provide greater understanding of the most aggressive type of skin cancer (Melanoma) Target Melanoma will provide greater understanding of the most aggressive type of skin cancer (Melanoma)
  • APO-DECIDE will create comprehensive tools and tests to predict which patients will benefit from chemotherapy APO-DECIDE will create comprehensive tools and tests to predict which patients will benefit from chemotherapy

Partnering

OncoMark PartneringOncoMark has invested in R&D and in-licensing of IP for diagnostic assay development. We believe that Rx-Dx partnering should begin as early as possible in the development process.

Every winning partnership starts with a simple decision Click for more details »

Products

IHC-Mark and Biomarker Interpretation Workflow OncoMark has developed proprietary Prognostic & Predictive Biomarkers panels. Our research validated software IHC-Mark provides automated nuclear, cytoplasmic and membraneous IHC stain quantitation.
Another time-saving product is our Biomarker Interpretation Workflow platform. We also have a range of new assays & IP in development.

View current products
»
 

Research Projects



 

 

Subscribe to RSS FeedCompany News

November 2014 - OncoMark is nominated in 4 categories in the Irish Laboratory Awards 2014
OncoMark has been nominated for 4 awards as part of the Irish Laboratory Awards 2014. The Company has been shortlisted in the following categories; BioScience Laboratory of the Year Research Laboratory of the Year Medical Laboratory of the Year Laboratory Team of the Year » read more
July 2014 - Dr Máirín Rafferty, CEO, interviewed by Irish Times for Melanoma article
'Be good to your skin, it's the first line of defence' by Dick Ahlstrom for the Irish Times. Dr Máirín Rafferty, CEO, interviewed by the Irish Times for a piece about research into Melanoma. » read more
March 2014 - OncoMark Researcher presents AngioTox/AngioPredict work in recent public lecture at RCSI
Dr David Murray (seconded to OncoMark from RCSI) presents AngioTox and AngioPredict project work. » read more

Subscribe to RSS FeedIndustry News

November 2014 - RCSI led colorectal cancer research project advancing improved individual treatments for patients
APO_DECIDE predictive tools could improve therapy for 70% of non-responding stage 2 & 3 patients. » read more
April 2014 -OncoMark Researcher presents poster at AACR Conference in San Diego, CA
The American Association for Cancer Research annual meeting was held recently in San Diego, California. This conference is the most important meeting for cancer researchers. With more than 15.000 delegates, it brings together worldwide experts in any field of cancer research. » read more
September 2013 - 16th International Conference on Medical Imaging and Computer Assisted Intervention - Nagoya, Japan
MICCAI 2013, the 16th International Conference on Medical Image Computing and Computer Assisted Intervention, was held from September 22nd to 26th, 2013 in Nagoya, Japan, organized with Scientific Council of Japan. MICCAI attracts annually world leading scientists, engineers and clinicians from a wide range of disciplines associated with medical imaging and computer assisted surgery. Dr JesuChristopher Joseph attended on behalf of OncoMark. » read more